{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:15Z","timestamp":1792511475077,"version":"4.5.0"},"reference-count":34,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Public Health Surveill"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Despite the vast growth of vaccine studies during the SARS-CoV-2 pandemic, clinical trials failed to adequately represent diverse societal groups, resulting in the underrepresentation of specific populations. Understanding the factors hampering participation in vaccine clinical trials is essential to better identify structural, ethical, and communication barriers and to improve inclusive strategies for broader and more equitable participation in future vaccine research.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aimed to identify the perceived barriers to participation in vaccine trials among pregnant and lactating women, children aged younger than 18 years, and adults aged older than 65 years, as reported by professionals with expertise in vaccines or vaccine trials.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n An online questionnaire was developed to gather personal information, group-specific barriers to vaccine trial participation, and suggestions to overcome these barriers. Data are presented as absolute (n\/N) and relative frequencies (%).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 115 respondents, the majority (n=73, 63.5%) of whom were working in the scientific community, completed the online survey. Challenges in recruiting children were identified due to \u201csafety or efficacy concerns,\u201d \u201cdifficulties about ethics and regulatory issues,\u201d and \u201clack of targeted information and communication.\u201d Challenges in recruiting pregnant and lactating women were primarily \u201cethics and regulatory requirements,\u201d \u201csafety issues,\u201d and \u201clack of prioritization or interest.\u201d \u201cLack of information and communication channels adapted to the specific target group,\u201d along with \u201clack of prioritization,\u201d were the main challenges in recruiting older participants. Provision of health-related incentives, including but not limited to access to new treatments and receiving expert medical care, seems to be the top-rated motivation to participate in vaccine clinical trials.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The main challenges in recruiting pregnant and lactating women and children in vaccine trials involve safety and efficacy concerns, as well as lengthy ethical and regulatory processes. For older adults, key issues include poor communication channels tailored to their needs, limited information, lack of prioritization, funding, infrastructure, and industry interest. Across all underrepresented groups, low awareness of and poor communication about research opportunities were major barriers. Additionally, mobility issues affected older adults, while lack of motivation and incentives affected children, and low health literacy and provider uncertainty impacted pregnant and lactating women. Improving communication infrastructure and enhancing communication strategies with clear, tailored messages to build trust and motivate participation are essential to improve inclusion in vaccine research.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/89025","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T19:42:52Z","timestamp":1775590972000},"page":"e89025-e89025","source":"Crossref","is-referenced-by-count":1,"title":["Barriers and Opportunities to Include Underrepresented Population Groups in Vaccine Trials: Cross-Sectional, Observational, Online Survey Study From the VACCELERATE Research Network"],"prefix":"10.2196","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9565-4389","authenticated-orcid":false,"given":"Mine Durusu","family":"Tanriover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-9620","authenticated-orcid":false,"given":"Dimitrios","family":"Poulimeneas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3662-0140","authenticated-orcid":false,"given":"Grammatiki-Christina","family":"Tsopela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6499-4807","authenticated-orcid":false,"given":"Ioannis","family":"Kopsidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2090-2162","authenticated-orcid":false,"given":"Christos","family":"Argyropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8715-0348","authenticated-orcid":false,"given":"Romina","family":"Di Marzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7882-2635","authenticated-orcid":false,"given":"Olena","family":"Valdenmaiier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2586-0248","authenticated-orcid":false,"given":"Stine Finne","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3399-9725","authenticated-orcid":false,"given":"Paula","family":"Valle Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1823-4174","authenticated-orcid":false,"given":"Antonio Javier","family":"Carcas-Sansuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3025-2466","authenticated-orcid":false,"given":"Ole F","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5893-1081","authenticated-orcid":false,"given":"Zoi Dorothea","family":"Pana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0127-6562","authenticated-orcid":false,"given":"Theoklis","family":"Zaoutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6904-9473","authenticated-orcid":false,"given":"Murat","family":"Akova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106740","article-title":"Inclusion and diversity in clinical trials: actionable steps to drive lasting change","volume":"116","author":"Kelsey","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"R2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamainternmed.2022.5600","article-title":"Sex, racial, and ethnic representation in COVID-19 clinical trials: a systematic review and meta-analysis","volume":"183","author":"Xiao","journal-title":"JAMA Intern Med"},{"issue":"1","key":"R3","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-10-92","article-title":"Reaching the hard to reach--lessons learned from the VCS (voluntary and community sector). A qualitative study","volume":"10","author":"Flanagan","journal-title":"BMC Health Serv Res"},{"issue":"37","key":"R4","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.1016\/j.vaccine.2019.06.081","article-title":"Defining hard-to-reach populations for vaccination","volume":"37","author":"Ozawa","journal-title":"Vaccine (Auckl)"},{"issue":"2","key":"R5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37640","article-title":"Assessment of the inclusion of racial\/ethnic minority, female, and older individuals in vaccine clinical trials","volume":"4","author":"Flores","journal-title":"JAMA Netw Open"},{"issue":"35","key":"R6","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.1016\/j.vaccine.2023.06.073","article-title":"Exclusion of pregnant people from emergency vaccine clinical trials: a systematic review of clinical trial protocols and reporting from 2009 to 2019","volume":"41","author":"Minchin","journal-title":"Vaccine (Auckl)"},{"issue":"10","key":"R7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0312799","article-title":"Understanding the barriers and enablers to participation in vaccine trials in a pregnant population from diverse ethnic background in an inner-city UK hospital","volume":"19","author":"Youssef","journal-title":"PLoS One"},{"issue":"6","key":"R8","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/cts.13077","article-title":"COVID-19 vaccine hesitancy: race\/ethnicity, trust, and fear","volume":"14","author":"Willis","journal-title":"Clin Transl Sci"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.128183","article-title":"Enablers and barriers to participation in vaccine trials: a narrative synthesis","volume":"73","author":"Daniel","journal-title":"Vaccine (Auckl)"},{"key":"R10","unstructured":"CanSino Biologics Inc. A study to evaluate the safety and immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in coronavac immunized children and adolescents. ClinicalTrials.gov. Jun 15, 2023. URL: https:\/\/clinicaltrials.gov\/study\/NCT05169008 [Accessed 04-12-2025]"},{"issue":"12","key":"R11","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11121784","article-title":"The challenges of vaccine trial participation among underserved and hard-to-reach communities: an internal expert consultation of the VACCELERATE consortium","volume":"11","author":"Poulimeneas","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"R12","doi-asserted-by":"publisher","DOI":"10.22323\/2.21050205","article-title":"Vaccination rates in Europe are not associated with online media intensity","volume":"21","author":"Lu\u00eds","journal-title":"JCOM"},{"issue":"31","key":"R13","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1016\/j.vaccine.2022.05.022","article-title":"VACCELERATE Volunteer Registry: a European study participant database to facilitate clinical trial enrolment","volume":"40","author":"Salmanton-Garc\u00eda","journal-title":"Vaccine (Auckl)"},{"issue":"26","key":"R14","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1016\/j.vaccine.2023.05.006","article-title":"VACCELERATE Site Network: real-time definition of clinical study capacity in Europe","volume":"41","author":"Salmanton-Garc\u00eda","journal-title":"Vaccine (Auckl)"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.2196\/44491","article-title":"Enhancing public health communication regarding vaccine trials: design and development of the Pan-European VACCELERATE toolkit","volume":"9","author":"Argyropoulos","journal-title":"JMIR Public Health Surveill"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.2196\/47241","article-title":"Perspectives of European Patient Advocacy Groups on Volunteer Registries and Vaccine Trials: VACCELERATE survey study","volume":"10","author":"Themistocleous","journal-title":"JMIR Public Health Surveill"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.2196\/65590","article-title":"Data interoperability in COVID-19 vaccine trials: methodological approach in the VACCELERATE project","volume":"13","author":"Malik","journal-title":"JMIR Med Inform"},{"key":"R18","unstructured":"New publication: self-testing for respiratory viruses. VACCELERATE. URL: https:\/\/vaccelerate.eu [Accessed 04-12-2025]"},{"key":"R19","unstructured":"VACCELERATE stakeholder survey. LimeSurvey. URL: https:\/\/lime.omega-cro.com.tr\/index.php\/422312?newtest=Y&lang=en [Accessed 04-12-2025]"},{"issue":"1","key":"R20","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2023.611","article-title":"Barriers and facilitators to recruitment of underrepresented research participants: perspectives of clinical research coordinators","volume":"7","author":"Heffernan","journal-title":"J Clin Transl Sci"},{"issue":"1","key":"R21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/heq.2024.0184","article-title":"Qualitative study of health care professional perspectives on recruiting minority patients in cancer trials","volume":"9","author":"Price","journal-title":"Health Equity"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.2147\/JHL.S488426","article-title":"Barriers to recruitment and retention among underrepresented populations in cancer clinical trials: a qualitative study of the perspectives of clinical trial research coordinating staff at a cancer center","volume":"16","author":"Yousafi","journal-title":"J Healthc Leadersh"},{"issue":"9","key":"R23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000065.pub2","article-title":"Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis","volume":"9","author":"Meskell","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"R24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.pharma.2020.03.003","article-title":"Vaccine distrust: investigation of the views and attitudes of parents in regard to vaccination of their children","volume":"78","author":"Caudal","journal-title":"Ann Pharm Fr"},{"issue":"44","key":"R25","doi-asserted-by":"publisher","first-page":"6633","DOI":"10.1016\/j.vaccine.2019.09.048","article-title":"Barriers and motivations for participation in preventive vaccine clinical trials: experience of 5 clinical research sites","volume":"37","author":"Detoc","journal-title":"Vaccine (Auckl)"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2024.100585","article-title":"Parental motivations and perceived barriers to participating in pediatric vaccine clinical trials: findings from the OCV-S trial in Nepal","volume":"21","author":"Chapagain","journal-title":"Vaccine X"},{"issue":"8","key":"R27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2307\/3824796","article-title":"Social capital and public affairs","volume":"47","author":"Putnam","journal-title":"Bulletin of the American Academy of Arts and Sciences"},{"issue":"1","key":"R28","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1186\/s12889-022-14562-2","article-title":"Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study","volume":"22","author":"Terraneo","journal-title":"BMC Public Health"},{"key":"R29","unstructured":"Deverez volontaire pour tester les vaccins! COVIREIVAC. URL: www.covireivac.fr [Accessed 04-12-2025]"},{"issue":"6","key":"R30","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2109364","article-title":"A national platform for COVID-19 vaccine studies recruitment in France: Covireivac volunteer\u2019s characteristics","volume":"18","author":"Bonneton","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"R31","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101208","article-title":"Characterization of individuals interested in participating in a phase I SARS-CoV-2 vaccine trial","volume":"9","author":"Shamsrizi","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"R32","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15081743","article-title":"Willingness to participate in vaccine-related clinical trials among older adults","volume":"15","author":"Raheja","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"R33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263362","article-title":"Correction: Healthy volunteers in US phase I clinical trials: sociodemographic characteristics and participation over time","volume":"17","author":"Kalbaugh","journal-title":"PLoS ONE"},{"issue":"10","key":"R34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258858","article-title":"Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment","volume":"16","author":"Andrasik","journal-title":"PLoS ONE"}],"container-title":["JMIR Public Health and Surveillance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publichealth.jmir.org\/2026\/1\/e89025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:15:16Z","timestamp":1782839716000},"score":1,"resource":{"primary":{"URL":"https:\/\/publichealth.jmir.org\/2026\/1\/e89025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":34,"URL":"https:\/\/doi.org\/10.2196\/89025","relation":{},"ISSN":["2369-2960"],"issn-type":[{"value":"2369-2960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"article-number":"v12i1e89025"}}